Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Immunitybio, Inc.

Clinical trials sponsored by Immunitybio, Inc., explained in plain language.

ImmunityBio, Inc. IBRX NASDAQ

Immunotherapy biotech developing cancer treatments.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 10 Not yet recruiting 5 Not yet finished but already full! 15 Completed 3 Terminated 1

Lung cancer drug combo trial halted midway – what we know

Disease control Terminated

This study tested a new drug called nogapendekin alfa inbakicept combined with standard treatments for people with advanced or metastatic non-small cell lung cancer. The trial was stopped early, so results are limited. It involved 102 adults who had not received prior chemotherap…

Phase: PHASE3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:38 UTC